Journal article
Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
The oncologist (Dayton, Ohio), Vol.25(11), pp.e1711-e1719
11/2020
DOI: 10.1634/theoncologist.2020-0334
PMCID: PMC7648343
PMID: 32790011
Abstract
Dysregulated fibroblast growth factor receptor (FGFR) signaling is associated with several cancers, including urothelial carcinoma. Preclinical studies with FGFR inhibitors have shown significant antitumor activity, which has led to clinical evaluation of multiple FGFR inhibitors. Recently, erdafitinib was approved by the U.S. Food and Drug Administration for advanced urothelial carcinoma with FGFR gene alterations as the first molecularly targeted therapy. Additional ongoing clinical trials with other types of FGFR inhibitors have shown encouraging results. This review summarizes the oncogenic signaling of FGFR alterations, completed and ongoing clinical trials of FGFR inhibitors, and resistance patterns.
Implications for Practice
Dysregulated fibroblast growth factor receptor (FGFR) signaling is associated with several cancers, including urothelial carcinoma. Preclinical studies with FGFR inhibitors have shown significant antitumor activity, which has led to clinical evaluation of multiple FGFR inhibitors. Most recently, erdafitinib was approved by the U.S. Food and Drug Administration for advanced urothelial carcinoma with FGFR gene alterations as the first molecularly targeted therapy. Additional ongoing clinical trials with other types of FGFR inhibitors have shown encouraging results. This review summarizes the oncogenic signaling of FGFR alterations, completed and ongoing clinical trials of FGFR inhibitors, and resistance patterns.
Details
- Title: Subtitle
- Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
- Creators
- Rohan Garje - University of IowaJosiah An - University of IowaMohammad Obeidat - University of IowaKranthi Kumar - Department of Pathology and Lab Medicine, AIIMSHesham A. Yasin - University of IowaYousef Zakharia - University of Iowa
- Resource Type
- Journal article
- Publication Details
- The oncologist (Dayton, Ohio), Vol.25(11), pp.e1711-e1719
- DOI
- 10.1634/theoncologist.2020-0334
- PMID
- 32790011
- PMCID
- PMC7648343
- NLM abbreviation
- Oncologist
- ISSN
- 1083-7159
- eISSN
- 1549-490X
- Publisher
- John Wiley & Sons, Inc
- Alternative title
- FGFR Inhibitors in Urothelial Cancer
- Language
- English
- Date published
- 11/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984548265302771
Metrics
5 Record Views